All In Biotech

Drug Trial Radar · NCT07416968

Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study

Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study (WoMEN'S)

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Sep 1, 2025

Primary completion

Sep 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Mansoura UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cairo University; Ain Shams University; Alexandria University; Zagazig University; Tanta University; Menoufia University; Assiut University; Sohag University; South Valley University; Beni-Suef University; Minia University; Aswan University
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage. Women who join the study will be randomly placed into one of two groups: One group will take tadalafil (5 mg), a medicine taken once a day. The other group will take solifenacin (5 mg), a common treatment for OAB, also taken once a day. The study will last 12 weeks. Participants will keep a bladder diary, answer short questionnaires, and have simple urine flow and bladder tests at several visits. The main goal is to find out which medicine lowers OAB symptoms more, such as urgency and frequent urination. Researchers will also look at quality of life, bladder function, and side effects. Women aged 18 to 75 years with OAB symptoms for at least 3 months may be able to take part.

Conditions

  • Overactive Bladder (OAB)
  • Overactive Bladder Syndrome

Interventions

  • Tadalafil 5 mgDrug

    Tadalafil 5 mg orally once daily for the duration of 12 weeks

  • Solifenacin 5mgDrug

    solifenacin succinate 5 mg orally once daily for the duration of 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overactive Bladder Symptom Score percentage reductionTime frame: from enrollment to 12 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Faculty of medicine, minia university

    Al Minyā, Egypt · Recruiting

  • Faculty of medicine, Alexandria University

    Alexandria, Egypt · Recruiting

  • Faculty of medicine, Aswan university

    Aswān, Egypt · Recruiting

  • Faculty of Medicine - Assiut University

    Asyut, Egypt · Recruiting

  • Faculty of Medicine - Banī Suwayf University

    Banī Suwayf, Egypt · Recruiting

  • Faculty of medicine, Ain Shams University

    Cairo, Egypt · Recruiting

  • Cairo University, faculty of medicine

    Cairo, Egypt · Recruiting

  • Faculty of Medicine, South Valley University

    Qina, Egypt · Recruiting

  • Faculty of medicine, Sohag Univeristy

    Sohag, Egypt · Recruiting

  • Faculty of medicine, Menofia Univeristy

    Shibīn al Kawm, Al-Minūfiyyah, Egypt · Recruiting

  • Faculty of medicine, Zagazig University

    Zagazig, Al-Sharqia, Egypt · Recruiting

  • Urology and Nephrology Center, Mansoura University

    Al Mansurah, Dakahlia Governorate, Egypt · Recruiting

  • Faculty of medicine, Tanta University

    Tanta, Gharbia Governorate, Egypt · Recruiting

  • faulty of medicine, Tanta Univeristy

    Tanta, Gharbia Governorate, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.